Understanding how a specific genetic change leads to acute myeloid leukemia
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
This study is looking at a specific genetic change linked to acute myeloid leukemia (AML) to see how it helps the disease grow and change, with the hope of finding better and safer treatments for people with AML.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10877191 on NIH RePORTER |
What this research studies
This research investigates the role of a genetic alteration known as the t(8;21) translocation, which is commonly associated with acute myeloid leukemia (AML). The study aims to uncover how this alteration contributes to the development of AML by promoting additional mutations. Using advanced techniques like CRISPR/Cas9 and precision nuclear run-on transcription sequencing, researchers will analyze the effects of the AML1-ETO fusion protein on gene regulation and epigenetic changes. This understanding could lead to the development of more effective and less harmful treatments for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with the t(8;21) genetic alteration.
Not a fit: Patients with other types of leukemia or those without the t(8;21) translocation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for acute myeloid leukemia that are less debilitating and more effective.
How similar studies have performed: Other research has shown promise in understanding genetic alterations in leukemia, making this approach both relevant and potentially impactful.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Hiebert, Scott W — Vanderbilt University
- Study coordinator: Hiebert, Scott W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.